CASI Pharmaceuticals Inc - ESG Rating & Company Profile powered by AI
The Disclosure score covers seventeen United Nations Sustainable Development Goals including: 'Quality Education', 'Sustainable Cities & Communities' and 'Partnerships for the Goals'. The article contains a questions and answers section about CASI Pharmaceuticals Inc. Alternative companies in the rating industry group for CASI Pharmaceuticals Inc are shown.
CASI Pharmaceuticals Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.0; made up of an environmental score of 5.3, social score of 1.6 and governance score of 8.0.
5.0
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 724 | Skye Bioscience Inc | 5.1 | High |
| 724 | Xbrane Biopharma AB | 5.1 | High |
| 744 | CASI Pharmaceuticals Inc | 5.0 | High |
| 744 | CSL Ltd | 5.0 | High |
| 744 | CStone Pharmaceuticals | 5.0 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does CASI Pharmaceuticals Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes CASI Pharmaceuticals Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes CASI Pharmaceuticals Inc report the average age of the workforce?
Sign up for free to unlockDoes CASI Pharmaceuticals Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes CASI Pharmaceuticals Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes CASI Pharmaceuticals Inc disclose cybersecurity risks?
Sign up for free to unlockDoes CASI Pharmaceuticals Inc offer flexible work?
Sign up for free to unlockDoes CASI Pharmaceuticals Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes CASI Pharmaceuticals Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes CASI Pharmaceuticals Inc conduct supply chain audits?
Sign up for free to unlockDoes CASI Pharmaceuticals Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes CASI Pharmaceuticals Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes CASI Pharmaceuticals Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes CASI Pharmaceuticals Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes CASI Pharmaceuticals Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes CASI Pharmaceuticals Inc disclose water use targets?
Sign up for free to unlockDoes CASI Pharmaceuticals Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid CASI Pharmaceuticals Inc have a product recall in the last two years?
Sign up for free to unlockDoes CASI Pharmaceuticals Inc disclose incidents of discrimination?
Sign up for free to unlockDoes CASI Pharmaceuticals Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas CASI Pharmaceuticals Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes CASI Pharmaceuticals Inc disclose parental leave metrics?
Sign up for free to unlockDoes CASI Pharmaceuticals Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes CASI Pharmaceuticals Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes CASI Pharmaceuticals Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes CASI Pharmaceuticals Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes CASI Pharmaceuticals Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes CASI Pharmaceuticals Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs CASI Pharmaceuticals Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes CASI Pharmaceuticals Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes CASI Pharmaceuticals Inc disclose its waste policy?
Sign up for free to unlockDoes CASI Pharmaceuticals Inc report according to TCFD requirements?
Sign up for free to unlockDoes CASI Pharmaceuticals Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes CASI Pharmaceuticals Inc disclose energy use targets?
Sign up for free to unlockDoes CASI Pharmaceuticals Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes CASI Pharmaceuticals Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for CASI Pharmaceuticals Inc
These potential risks are based on the size, segment and geographies of the company.
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.